Clinical Trials Browser

NCT07445048 2026-04-17

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Phase 3 Recruiting

370 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07457528 2026-03-11

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

Phase 2 Recruiting

46 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04821778 2026-01-21

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Phase 3 Recruiting

2,000 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT04821843 2026-01-21

Neoadjuvant Treatment Modalities in Esophageal Cancer

Phase 3 Recruiting

2,000 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Phase 2 Recruiting

10 enrolled

Head & Neck

Pathologic Complete Response, Head and Neck Neoplasms

NCT07333274 2026-01-12

Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Recruiting

335 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06770452 2025-09-23

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Phase 2 Recruiting

32 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06509009 2025-09-19

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Recruiting

30 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Phase 2 Recruiting

208 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06988956 2025-05-25

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

Phase 2 Recruiting

95 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06912711 2025-05-21

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Phase 2 Recruiting

70 enrolled

Head & Neck

Nasopharyngeal Carcinoma